The role of hormone replacement therapy in the treatment of women with complicated chronic renal failure;Perspektywy stosowania hormonalnej terapii zastȩpczej u kobiet w leczeniu powikłań przewlekłej niewydolności nerek

Polski Merkuriusz Lekarski

Volumn 14, Issue 80, 2003, Pages 163-167

  Kos Kudła, Beata ^a,b,c   Staszewicz, Paweł ^a,b  

^a AM   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c SI AM   (Poland)

Author keywords

cardiovascular complications; Chronic renal failure; estradiol; hormonal replacement therapy; renal osteodystropy

Indexed keywords

ESTROGEN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; EARLY MENOPAUSE; ENDOCRINE DISEASE; ESTROGEN DEFICIENCY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RENAL OSTEODYSTROPHY; REVIEW; RISK BENEFIT ANALYSIS; DRUG EFFECT; ESTROGEN THERAPY; MENOPAUSE; MIDDLE AGED;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MENOPAUSE; MIDDLE AGED; RENAL OSTEODYSTROPHY;

EID: 17444440635     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Agodoa L.Y. i wsp.: End-stage renal disease in the USA: Data from the United States Renal Data System. Am J Nephrol, 1996, 16, 7-16.
2. Alem A.: Increased risk of hip fracture among patients with end stage renal disease Kidney Int. 2000, 58, 396-399.
3. Bostom A.G., Lathrop L.: Hyperhomocysteinemia in end stage renal disease: Prevalence. etiology and potential relationship to arteriosclerotic outcomes. Kidney Int, 1997, 52, 10-20.
4. Castelli W.P.: Menopause and cardiovascular disease. W: B.A. Eskin (red.) The menopause: comprehensive management. The Partenon Publishing Group, New York 2000. 117-135.
5. Cochrane R., Regan L.: Undetected gynecological disorders in woman with renal disease. Hum Reprod, 1997, 12, 667-670.
6. Cummings S.: Prevention of hip fractures in older women: A population-based perspective. Osteoporos Int, 1998, 8, 8-12.
7. Di Minno G, i wsp.: Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med, 1985, 79, 552-9.
8. Evans S., Davle M.: Low and conventional dose transdermal estradiol and equally effective at preventing bone loss in spine and femur at all postmenopausal ages. Clin Endocrinol, 1996, 44, 79-84.
9. Falkeborn M. i wsp.: The risk of acute myocardial infarction after oestrogen and oestrogen-progestagen replacement. Br J Obstet Gynaecol, 1992, 99, 821-828.
10. Field C. i wsp.: Preventive effects of transdermal 17 β-estradiol on osteoporotic changes after surgical menopause: a 2 year placebo-controlled trial, Am J Obst Gynaecol, 1993, 168, 114-121.
11. , Folsom A.R. i wsp.: Determinants population changes in fibrinogen and factor VII over 6 years, The Atherosclerosis Risk in Communities (ARIC) Study, Arterioscler Thromb Vasc Biol, 2000, 20, 601-606.
12. Ginsburg E.S. i wsp.: Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int, 1998, 54, 1344-50.
13. Godsland I.F. i wsp.: Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy Metabolism, 1993, 42, 846-53.
14. Grodstein G. i wsp.: Hormone replacement inwomen with established arterial disease. W: M. Whitehead (red.) The prescriber's guide to hormone replacement therapy. The Partenon Publishing Group, New York 1998, 177-181.
15. Gupta A. i wsp.: Increased risk of hip fractures in US Medicare end-stage renal disease patients. J Bone Miner Res, 1997, 12, S274.
16. Holley J.L. i wsp.: Gynecological and reproductive issues in women on dialysis. Am J Kidney Dis, 1997, 29, 685-690.
17. Horowitz M.C.: Cytokines and estrogen in bone: antiosteoporotic effects. Science, 1993, 260, 626-627.
18. Lindsay R., Tohme J.F.; Oestrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynaecol, 1990, 76, 290-295.
19. Livio M. i wsp.: Conjugated estrogens for the management of bleeding associated with renal failure. N Eng] J Med, 1986, 315, 731-5.
20. Matuszkiewicz-Rowińska J. i wsp,: Hormonalna terapia zastȩpcza a gospodarka lipidowa u kobiet dializowanych z wtȯrnym do mocznicy niedoborem estrogenów. Pol Arch Med Wewn, 1999, 2, 671-676.
21. Matuszkiewicz-Rowinska J. i wsp.: Hormonalna terapia zastȩpcza w zapobieganiu utracie minerału kostnego u koblet w wieku rozrodczym z niedoborem estradiolu leczonych powtarzanymi dializami pozaustrojowymi. Pol Arch Med Wewn, 1999, 2, 665-670.
22. Mijatovic V. i wsp.: A randomized controlled study of the effects of 17 beta estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol, 1998, 91, 432-6.
23. Pallas K.G. i wsp.: The effect of conjugated estrogens on the renin-angiotensin system. J Clin Endocrinol Metab, 1977, 44, 1061-8.
24. Pereira B.J.G. i wsp.: Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure. CAPD and hemodialyzed patients. Kidney Int, 1993, 45, 890-896.
25. Proudler A.J. i wsp.: Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet, 1995, 346, 89-90.
26. Rabelink T.J, i wsp.: Thrombosis and hemostasis in renal disease. Kidney Int, 1994, 46, 287-296.
27. Robinson K. i wsp.: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation, 1996, 94, 2743-2748.
28. Roe S. i wsp.: Diagnosis and monitoring of renal osteodystrophy Curr Opin Nephrol Hypertens, 2000, 9, 675-81.
29. Schunkert H. i wsp.: Effects of estrogen replacement therapy on the reninangiotensin system in postmenopausal women. Circulation, 1997, 95, 39-45.
30. Sidney C.S. i wsp.: AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. Circulation, 2001, 104, 1577-1579.
31. Silver J, i wsp.: Oestrogen deficiency-does it have a role in the genesis of skeletal problems in dialysed women?, Nephrol Dial Transplant, 1996, 11, 565-6.
32. Skafar D.F. i wsp.: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab, 1997, 82, 3913-18.
33. Smolenski O.: Zaburzenia w układzie kra̧żenia. W: B. Rutkowski: Dializoterapia w codziennej praktyce. Wyd. Med., Gdańsk 1996, 266-275.
34. Stevenson J.C.: Assessment of therapeutic option of bone loss. W: C. Christiansen i wsp. (red.) Osteoporosis, Viborg: Norhaven Bogtryken AS, 1987, 489-93.
35. Sullivan J.M.: Practical Aspects of preventing and managing atherosclerotic disease in postmenopausal women. Eur Heart J. 1996, 17, 32-37.
36. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progesterone Interventions (PEPI) Trial. JAMA, 1995, 273 (3), 199-208.
37. Weisinger J.R. i wsp.: Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women, Kidney Int, 2000, 58, 331-335.